MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways-Reference-Cited by-同舟云学术

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways

Published:2014-04-23 Issue:8 Volume:5 Page:2030-2043
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Saiki Anne Y.¹,Caenepeel Sean¹,Yu Dongyin¹,Lofgren Julie A.¹,Osgood Tao¹,Robertson Rebecca¹,Canon Jude¹,Su Cheng²,Jones Adrie³,Zhao Xiaoning³,Deshpande Chetan⁴,Payton Marc¹,Ledell Jebediah⁵,Hughes Paul E.¹,Oliner Jonathan D.¹

Affiliation:

1. Department of Oncology Research, Amgen, Thousand Oaks, CA

2. Department of Biostatistics, Amgen, Seattle, WA

3. Department of Molecular Structure and Characterization, Amgen, South San Francisco, CA

4. Department of Molecular Sciences and Computational Biology, Amgen, Thousand Oaks, CA

5. Department of Biology, Zalicus, Cambridge, MA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification;JCO Precision Oncology;2024-09

2. Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression;International Journal of Molecular Sciences;2024-02-13

3. Translating p53-based therapies for cancer into the clinic;Nature Reviews Cancer;2024-01-29

4. Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens;Saudi Pharmaceutical Journal;2023-10

5. MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation;Biomedicines;2023-07-02